Skip to main content
JW LIFESCIENCE CORPORATION logo

JW LIFESCIENCE CORPORATION — Investor Relations & Filings

Ticker · 234080 ISIN · KR7234080000 KO Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2020-02-12 Earnings Release
Country KR South Korea
Listing KO 234080

About JW LIFESCIENCE CORPORATION

https://www.jw-lifescience.co.kr/lifesc…

JW LIFESCIENCE CORPORATION is a specialized manufacturer focused on the development and production of infusion solutions. The company's product portfolio includes a comprehensive range of intravenous (IV) fluids, from basic solutions to advanced nutrient infusions containing essential components such as amino acids, lipids, proteins, vitamins, and minerals. A key area of innovation is the development of high-value-added products, including multi-chambered infusion solutions. The company operates world-class manufacturing facilities and maintains dedicated research and development centers to support its commitment to producing high-quality medical fluids for patient treatment.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 95% confidence The document is a regulatory filing from a Korean company (JW Life Science) announcing a significant change in financial results (30% or more change in revenue or profit structure). This is a standard preliminary earnings announcement required by the Korea Exchange (KRX) for listed companies. It provides key financial highlights (revenue, operating profit, net income) and explicitly states that these are preliminary figures subject to audit. This fits the definition of an Earnings Release (ER), as it is the initial announcement of periodical financial results. FY 2019
2020-02-12 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea (often referred to as the '5% rule' report). It details the shareholding changes of Baring Asset Management in JW Life Science. Since this document is a formal notification of significant share ownership changes (crossing thresholds) and does not fit into other specific categories like 'Director's Dealing' or 'Annual Report', it is classified as a Major Shareholding Notification.
2020-01-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a standard Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This document is a mandatory disclosure filed with the Financial Supervisory Service (FSS) and the Korea Exchange (KRX) when an executive or major shareholder changes their ownership stake in a company. This specific type of filing is categorized as 'Director's Dealing' (DIRS) in the provided schema, as it details personal shareholdings and transactions by a company executive (Kim Chang-il).
2020-01-08 Korean
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for JW Life Science, covering the period from January 1, 2019, to September 30, 2019. It contains detailed financial statements, management discussion, and operational data, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-14 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for JW Life Science, covering the period from January 1, 2019, to June 30, 2019. It contains detailed financial statements, business descriptions, management analysis, and governance information. As it is a comprehensive financial report for a period shorter than a full fiscal year (half-year) and includes substantive financial data, it is classified as an Interim/Quarterly Report. H1 2019
2019-08-14 Korean
[기재정정]사업보고서 (2018.12)
Audit Report / Information Classification · 98% confidence The document is a '정정신고(보고)' (Correction Report) for a previously filed '사업보고서' (Annual Report/Business Report). It details specific corrections made to sections regarding the Board of Directors and major contracts. Since this is a formal amendment to an existing Annual Report (10-K equivalent in the Korean market) and contains the full structure of the business report, it is classified as an Annual Report (10-K). FY 2018
2019-07-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.